Journal Article Summary
The article explores the potential of inhibiting tumor necrosis factor-alpha (TNF-α) as a strategy for preventing Alzheimer’s disease (AD) and improving cognitive function in individuals at risk for dementia. With the prevalence of AD on the rise and a high failure rate of existing drug therapies, there is a pressing need for effective preventive measures. The authors highlight that TNF-α inhibitors, which have shown promise in other inflammatory conditions, may offer a new avenue for addressing cognitive decline associated with AD.
To investigate this, the authors conducted a literature review of studies published before July 2019 that focused on TNF-α blocking agents and curcumin, another TNF-α inhibitor, in relation to AD. They found that large epidemiological studies indicated a significant reduction in the risk of developing AD among patients treated with etanercept, a TNF-α inhibitor. Additionally, smaller randomized controlled trials suggested improvements in cognitive performance for AD patients receiving etanercept, while a trial with Theracurmin, a bioavailable form of curcumin, also showed cognitive benefits and reductions in amyloid-β plaques and tau tangles in the brain.
Despite these promising findings, the article notes several limitations, including the need for larger, more rigorous studies to confirm the benefits of TNF-α inhibition for AD prevention. Patients should be aware of the potential side effects associated with TNF inhibitors, such as serious infections and other adverse reactions, while curcumin appears to have a milder side effect profile. It is essential for readers to discuss any interest in TNF-α inhibitors or curcumin with their healthcare professionals, especially if they are at risk for AD or have existing health conditions that may be affected by these treatments.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Torres-Acosta Noel, O’Keefe James H., O’Keefe Evan L., Isaacson Richard, Small Gary. Therapeutic Potential of TNF-α Inhibition for Alzheimer’s Disease Prevention. Journal of Alzheimer's Disease 2020. DOI: 10.3233/JAD-200711. PMID: 33016914. PMCID: PMC7739965.
Featured Pill Pals Product
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription may be required.
